Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc.

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study First interim analysis included 95 participants with confirmed cases of COVID-19 Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% (p <0.0001) Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and e

[urashimasan]

モデルナ

[oku1]

勇気づけられるプレスリリース。